Metabolic tumour volume of anal carcinoma on 18FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival

Jemal, 2013, Annual Report to the Nation on the Status of Cancer 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels, J. Natl. Cancer Inst., 105, 175, 10.1093/jnci/djs491

Glynne-Jones, 2014, Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up, Eur. J. Surg. Oncol., 40, 1165, 10.1016/j.ejso.2014.07.030

Nigro, 1983, Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal, Cancer, 51, 1826, 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L

UKCCCR, 1996, Anal Cancer Trial Working UK Party Co-ordinating Committee on Cancer Research Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin, Lancet, 348, 1049, 10.1016/S0140-6736(96)03409-5

Bartelink, 1997, J. Clin. Oncol., 15, 2040, 10.1200/JCO.1997.15.5.2040

Myerson, 2001, Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome, Radiother. Oncol., 61, 15, 10.1016/S0167-8140(01)00404-2

Goh, 2010, Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?, Int. J. Radiat. Oncol. Biol. Phys., 78, 715, 10.1016/j.ijrobp.2009.08.055

Scherrer, 1990, CT of malignant anal canal tumours, Radiographics, 10, 433, 10.1148/radiographics.10.3.2188307

Martoni, 2011, Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuant chemoradiation therapy and radical surgery for locally advanced rectal cancer, Ann. Oncol., 22, 650, 10.1093/annonc/mdq433

Duong, 2006, FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesopha-geal cancer, Eur. J. Nucl. Med. Mol. Imaging, 33, 770, 10.1007/s00259-005-0040-z

Gutte, 2005, Early clinical experience and impact of 18F-FDG PET, Nucl. Med. Commun., 26, 989, 10.1097/01.mnm.0000184940.06123.f0

Bassi, 2008, FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer, Int. J. Radiat. Oncol. Biol. Phys., 70, 1423, 10.1016/j.ijrobp.2007.08.043

Deantonio, 2008, FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma, Radiat. Oncol., 3, 29, 10.1186/1748-717X-3-29

Yoo, 2013, Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer, Clin. Oncol., 25, 33, 10.1016/j.clon.2012.08.007

Trautmann, 2005, Positron emission tomography for pre-treatment staging and posttreatment evaluation in cancer of the anal canal, Mol. Imaging Biol., 7, 309, 10.1007/s11307-005-0003-6

Cotter, 2006, FDG-PET/CT in the evaluation of anal carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 65, 720, 10.1016/j.ijrobp.2006.01.009

Nguyen, 2008, Assessing the impact of FDG-PET in the management of anal cancer, Radiother. Oncol., 87, 376, 10.1016/j.radonc.2008.04.003

Winton, 2009, The impact of 18-fluorodeoxyglucose positron emission tomography on the staging: management and outcome of anal cancer, Br. J. Cancer, 100, 693, 10.1038/sj.bjc.6604897

Krengli, 2010, FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma, Radiat. Oncol., 5, 10, 10.1186/1748-717X-5-10

Deantonio, 2016, Anal cancer FDG-PET standard uptake value: correlation with tumour characteristics, treatment response and survival, Radiol. Med., 121, 54, 10.1007/s11547-015-0562-9

Berghmans, 2008, J. Thorac. Oncol., 3, 6, 10.1097/JTO.0b013e31815e6d6b

Kidd, 2007, The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival, Cancer, 110, 1738, 10.1002/cncr.22974

Ogunbiyi, 1997, Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography, Ann. Surg. Oncol., 4, 613, 10.1007/BF02303744

Lee, 2007, Metabolic tumour burden predicts for disease progression and death in lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 69, 328, 10.1016/j.ijrobp.2007.04.036

Kidd, 2010, Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis, Radiother. Oncol., 95, 288, 10.1016/j.radonc.2010.02.019

Bazan, 2013, Metabolic tumour volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal, J. Nucl. Med., 54, 27, 10.2967/jnumed.112.109470

Schwarz, 2008, Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer, Int. J. Radiat. Oncol. Biol. Phys., 71, 180, 10.1016/j.ijrobp.2007.09.005

Day, 2011, FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy, Br. J. Cancer, 105, 498, 10.1038/bjc.2011.274